The term 'discontinuation syndrome' was coined with Eli Lilly sponsorship in 1997 to replace 'withdrawal,' deliberately minimizing the severity of SSRI cessation effects. Before 1997, the term was used exactly once. After Lilly's sponsored journal supplement, it appeared 12 times that year alone. Systematic reviews now estimate 33-56% of users experience withdrawal, often with 'substantial morbidity and functional impairment.' Millions were told these drugs were non-addictive.